Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. decreased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 35.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,003 shares of the company's stock after selling 17,724 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Genmab A/S were worth $630,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. raised its holdings in Genmab A/S by 20.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 249,468 shares of the company's stock worth $4,885,000 after purchasing an additional 42,361 shares in the last quarter. Blue Trust Inc. raised its holdings in Genmab A/S by 169.9% during the first quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock worth $145,000 after purchasing an additional 4,666 shares in the last quarter. QRG Capital Management Inc. raised its holdings in Genmab A/S by 213.7% during the first quarter. QRG Capital Management Inc. now owns 74,847 shares of the company's stock worth $1,465,000 after purchasing an additional 50,990 shares in the last quarter. Fifth Third Bancorp raised its holdings in Genmab A/S by 16.6% during the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company's stock worth $825,000 after purchasing an additional 6,015 shares in the last quarter. Finally, Park Avenue Securities LLC acquired a new stake in Genmab A/S during the first quarter worth approximately $276,000. Institutional investors and hedge funds own 7.07% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Wall Street Zen lowered shares of Genmab A/S from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Finally, Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $37.60.

Genmab A/S Price Performance

NASDAQ:GMAB traded down $0.03 on Friday, reaching $20.41. The stock had a trading volume of 1,125,763 shares, compared to its average volume of 1,233,905. The company has a market cap of $13.09 billion, a price-to-earnings ratio of 11.60, a P/E/G ratio of 6.69 and a beta of 0.94. The firm's fifty day moving average is $21.00 and its two-hundred day moving average is $20.72. Genmab A/S Sponsored ADR has a 12-month low of $17.24 and a 12-month high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The company had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. As a group, research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.